Pathwork Diagnostics announced a collaboration with Guy's and St Thomas' NHS Foundation Trust in London to conduct the first research study on the Pathwork Tissue of Origin Test in the UK.

The proof-of-concept study with the test, which helps diagnose the origin of difficult-to-identify tumors, will validate it for use in their institution, and give them information to help them determine the most effective, cancer-specific treatment regimen.

"We're extremely excited about entering into this partnership with Guy's and St Thomas' NHS Foundation Trust," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "In this study, pathologists and oncologists at Guy's and St Thomas' will not only be able to validate the test for use in their institution, but more importantly, soon be able to use information generated to help them determine the most effective, cancer-specific treatment regimen for hard-to-diagnose cases."

In the collaboration, Dr. Giuseppe Culora, the clinical director, and Dr. Eugene Halligan, the scientific director, are performing a proof-of-concept validation study. "Since patients with cancer of unknown primary have a very poor prognosis, we hope that with this novel diagnostic test our oncologists will have new information at their fingertips to guide treatment and be able to offer a better standard-of-care for our cancer patients," said Dr. Culora.

The Pathwork Tissue of Origin Test is already FDA-cleared in the United States.

Read the full press release at Pathwork Diagnostics.